Pinaki

Banerjee
Sep 17, 2019 19:28:40 EDT
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

IL-15 armored CAR-transduced NK cells against CD19 positive B cell tumors

3. Are you t he corresponding aut hor?

No.

C ertification

I certify that the information provided in this disclosure is complete and accurate.
Rafet Basar
Sep 17, 2019 16:34:28 EDT
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

IL-15 armored CAR-transduced NK cells against CD19 positive B cell tumors

3. Are you t he corresponding aut hor?

No.

C ertification

I certify that the information provided in this disclosure is complete and accurate.
Kai Cao
Sep 16, 2019 19:55:14 EDT
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

First-in-human trial of cord blood derived natural killer cells engineered to express IL-15 and a chimeric antigen receptor against CD19 in relapsed
B-cell malignancies

3. Are you t he corresponding aut hor?

No.

C ertification

I certify that the information provided in this disclosure is complete and accurate.
Richard Champlin
Sep 25, 2019 17:30:37 EDT
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

First in human trial of cord blood derived natural killer cells engineered to express IL-15 and a chimeric antigen receptor against CD19 in relapsed
B-cell malignancies

3. Are you t he corresponding aut hor?

No.

C ertification

I certify that the information provided in this disclosure is complete and accurate.
Evan Cohen
Sep 16, 2019 19:31:21 EDT
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

IL-15 armored CAR-transduced NK cells against CD19 positive B cell tumors

3. Are you t he corresponding aut hor?

No.

C ertification

I certify that the information provided in this disclosure is complete and accurate.
Ana Cortes
Sep 17, 2019 01:40:11 EDT
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

IL 15 armored CAR transduced NK cells against CD19 Positive B cell tumors

3. Are you t he corresponding aut hor?

Yes.

a. Please list t he ot her aut hors' names here.

May Daher Mecit kaplan

C ertification

I certify that the information provided in this disclosure is complete and accurate.
May Daher
Sep 17, 2019 10:19:14 EDT
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

IL-15 armored CAR-transduced NK cells against CD19 positive B cell tumors

3. Are you t he corresponding aut hor?

No.

C ertification

I certify that the information provided in this disclosure is complete and accurate.
Chitra Hosing
Sep 16, 2019 20:03:27 EDT
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

Company or Organizat ion

Ent it y T ype Int erest Held By

Celgene Corporat ion Grant / Contract Self

Recipient Name: Chitra Hosing Recipient Type: Institution

Grant / Contract Description: Conduct of clinical trial Grant / Contract Purpose: Research
Additional Information:

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

2. What is t he manuscript t it le?

3. Are you t he corresponding aut hor?

C ertification

I certify that the information provided in this disclosure is complete and accurate.
Mecit Kaplan
Sep 18, 2019 12:23:41 EDT
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

IL-15 armored CAR-transduced NK cells against CD19 positive B cell tumors

3. Are you t he corresponding aut hor?

No.

C ertification

I certify that the information provided in this disclosure is complete and accurate.
Indreshpal Kaur
Sep 17, 2019 17:05:52 EDT
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

IL-15 armored CAR-transduced NK cells against CD19 positive B cell tumors

3. Are you t he corresponding aut hor?

No.

C ertification

I certify that the information provided in this disclosure is complete and accurate.
Michael Keating
Nov 06, 2019 15:32:13 EST
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

IL-15 armored CAR-transduced NK cells against CD19 positive B cell tumors

3. Are you t he corresponding aut hor?

No.

C ertification

I certify that the information provided in this disclosure is complete and accurate.
Partow Kebriaei
Sep 16, 2019 22:33:56 EDT
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

3. Are you t he corresponding aut hor?

No.

C ertification

I certify that the information provided in this disclosure is complete and accurate.
Enli Liu
Oct 07, 2019 15:55:52 EDT
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

Int ellect ual Propert y

T ype Is Licensed Int erest Held By

Pat ent - Met hods For Product ion Of CAR-NK Cells And Use T ... No Self

Description: Methods For Production Of CAR-NK Cells And Use Thereof Patent Number: U.S. Patent Application No. 62/826,856
Patent Status: Pending Patent Holder: Current Institution
Filing Jurisdiction: USA
Licensees: Additional Information:

Pat ent - Met hods Of T reat ment Wit h Nat ural Killer Cells M ... No Self

Description: Methods Of Treatment With Natural Killer Cells Matched For Patent Number: U.S. Patent Application No. 15/579,330
Killer Immunoglobulin Receptor Type Patent Status: Pending
Patent Holder: Current Institution Filing Jurisdiction: USA
Licensees: Additional Information:

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

IL-15 armored CAR-transduced NK cells against CD19 positive B cell tumors

3. Are you t he corresponding aut hor?

No.

C ertification

I certify that the information provided in this disclosure is complete and accurate.
Homer Macapinlac
Sep 24, 2019 07:24:11 EDT
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

First-in-human trial of cord blood derived natural killer cells engineered to express a chimeric antigen receptor against CD19 and IL-15 in relapsed
B-cell malignancies

3. Are you t he corresponding aut hor?

No.

C ertification

I certify that the information provided in this disclosure is complete and accurate.
David Marin
Sep 17, 2019 09:43:15 EDT
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

"IL-15 armored CAR-transduced NK cells against CD19 positive B cell tumors"

3. Are you t he corresponding aut hor?

No.

C ertification

I certify that the information provided in this disclosure is complete and accurate.
Rohtesh Mehta
Sep 17, 2019 08:15:51 EDT
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

First-in-human trial of cord blood derived natural killer cells engineered to express a chimeric antigen receptor against CD19 and IL-15 in relapsed
B-cell malignancies

3. Are you t he corresponding aut hor?

No.

C ertification

I certify that the information provided in this disclosure is complete and accurate.
Vandana Nandivada
Oct 03, 2019 13:10:16 EDT
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

NA

3. Are you t he corresponding aut hor?

No.

C ertification

I certify that the information provided in this disclosure is complete and accurate.
Lucila Nassif Kerbauy
Sep 17, 2019 08:55:07 EDT
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

IL-15 armored CAR-transduced NK cells against CD19 positive B cell tumors

3. Are you t he corresponding aut hor?

No.

C ertification

I certify that the information provided in this disclosure is complete and accurate.
Sattva Neelapu
Sep 23, 2019 22:48:58 EDT
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

Company or Organizat ion

Ent it y T ype Int erest Held By

Allogene T herapeut ics Consultant Self

Category: Consultant Consultant Description:

Contract Description: Consultant Additional Information:

Celgene Corporat ion Consultant Self

Category: Consultant Consultant Description:

Contract Description: Consultant Additional Information:

Cell Medica Inc Consultant Self

Category: Consultant Consultant Description:

Contract Description: Consultant Additional Information:

Gilead Sciences Inc Other Self

Category: Other Consultant Description:

Contract Description: Scientific Advisory Board Additional Information:

Gilead Sciences Inc Other Self

Category: Other Consultant Description:

Contract Description: Speaking Engagement Additional Information:

Gilead Sciences Inc Consultant Self

Category: Consultant Consultant Description:

Contract Description: Consultant Additional Information:

Incyt e Corporat ion Consultant Self

Category: Consultant Consultant Description:

Contract Description: Consultant Additional Information:

Legend Biot ech Consultant Self

Category: Consultant Consultant Description:

Contract Description: Consultant Additional Information:

Merck Consultant Self

Category: Consultant Consultant Description:

Contract Description: Consultant Additional Information:

Novart is Pharma Consultant Self

Category: Consultant Consultant Description:

Contract Description: Consultant Additional Information:

Pf izer Consultant Self

 Category: Consultant Consultant Description:
Contract Description: Consultant Additional Information:

Precision Biosciences, Inc Consultant Self

Category: Consultant Consultant Description:

Contract Description: Consultant Additional Information:

Unum T herapeut ics, Inc Consultant Self

Category: Consultant Consultant Description:

Contract Description: Consultant Additional Information:

Int ellect ual Propert y

T ype Is Licensed Int erest Held By

Pat ent - T CL1 vaccine t herapy of B-cell malignancies No Self

Description: TCL1 vaccine therapy of B-cell malignancies Patent Number: 9,290 ,541 B2
Patent Status: Issued Patent Holder: Discloser
Filing Jurisdiction: USA
Licensees: Additional Information:

Pat ent - Immune cells f or adopt ive cell t herapies No Self

Description: Immune cells for adoptive cell therapies Patent Number: 62/889,662
Patent Status: Pending Patent Holder: Discloser
Filing Jurisdiction: USA
Licensees: Additional Information:

Pat ent - Ant i-CD79b chimeric ant igen recept ors No Self

Description: Anti-CD79b chimeric antigen receptors Patent Number: 62/752,889

Patent Status: Pending Patent Holder: Discloser
Filing Jurisdiction: USA
Licensees: Additional Information:

Pat ent - T CL1-T CR f or immunot herapy No Self

Description: TCL1-TCR for immunotherapy Patent Number: 62/615,342

Patent Status: Provisional Patent Holder: Discloser
Filing Jurisdiction: USA
Licensees: Additional Information:

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

New England Journal of Medicine 19-10 60 7

3. Are you t he corresponding aut hor?

No.

C ertification
I certify that the information provided in this disclosure is complete and accurate.
Yago Nieto
Sep 24, 2019 09:52:50 EDT
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

First-in-human trial of cord blood derived natural killer cells engineered to express a chimeric antigen receptor against CD19 and IL-15 in relapsed
B-cell malignancies

3. Are you t he corresponding aut hor?

No.

C ertification

I certify that the information provided in this disclosure is complete and accurate.
Bethany Overman
Sep 17, 2019 09:00:38 EDT
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

IL-15 armored CAR-transduced NK cells against CD19 positive B cell tumors

3. Are you t he corresponding aut hor?

No.

C ertification

I certify that the information provided in this disclosure is complete and accurate.
Katy Rezvani
J an 08, 2020 17:30:10 EST
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

Int ellect ual Propert y

T ype Is Licensed Int erest Held By

Ot her Int ellect ual Propert y - Licensing of t echnology t o T akeda Yes Other - MD Anderson Cancer Center

Description: Licensing of technology to Takeda Type:

Licensees: Additional Information: The University of Texas M.D. Anderson Cancer
Licensee T it le Dat e Center has an institutional financial conflict of interest with Takeda
Pharmaceutical related to the research reported here, although the conflict
Takeda Oncology did not arise until after the completion of the manuscript. MD Anderson
has implemented an Institutional Conflict of Interest Management and
Monitoring Plan to manage and monitor the conflict of interest with respect
to MDACC's conduct of any other ongoing or future research related to this
relationship.

Ot her Int ellect ual Propert y - Licensing of t echnology t o T akeda Yes Self

Description: Licensing of technology to Takeda Type:

Licensees: Additional Information:
Licensee T it le Dat e

Takeda Oncology

Pat ent - Met hods For Product ion Of CAR-NK Cells And Use T ... No Self

Description: Methods For Production Of CAR-NK Cells And Use Thereof Patent Number: U. S. Patent Application No. 62/826,856
Patent Status: Pending Patent Holder: Current Institution
Filing Jurisdiction: USA
Licensees: Additional Information:

Pat ent - Met hods Of T reat ment Wit h Nat ural Killer Cells M ... No Self

Description: Methods Of Treatment With Natural Killer Cells Matched For Patent Number: U.S. Patent Application No. 15/579,330 ,
Killer Immunoglobulin Receptor Type, Patent Status: Pending
Patent Holder: Current Institution Filing Jurisdiction: USA
Licensees: Additional Information:

Pat ent - No Descript ion Provided No Self

Description: Patent Number:

Patent Status: Pending Patent Holder: Current Institution
Filing Jurisdiction: USA
Licensees: Additional Information:

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.
 2. What is t he manuscript t it le?

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

3. Are you t he corresponding aut hor?

Yes.

a. Please list t he ot her aut hors' names here.

Enli Liu, M.D., David Marin, M.D., Pinaki Banerjee, Ph.D., Homer A. Macapinlac, M.D., Philip Thompson, M.B., B.S., Rafet Basar, M.D.,
Lucila Nassif Kerbauy, M.D., Bethany Overman, B.S.N., Peter Thall, Ph.D., Mecit Kaplan, M.S., Vandana Nandivada, M.S., Indresh Kaur,
Ph.D., Ana Nunez Cortes, M.D., Kai Cao, M.D., May Daher, M.D., Chitra Hosing, M.D., Evan N. Cohen, Ph.D., Partow Kebriaei, M.D., Rohtesh
Mehta, M.D., Sattva Neelapu, M.D., Yago Nieto, M.D., Ph.D., Michael Wang, M.D., William Wierda, M.D., Ph.D., Michael Keating, M.D.,
Richard Champlin, M.D., Eliz abeth J. Shpall, M.D., and Katayoun Rez vani, M.D., Ph.D.

C ertification

I certify that the information provided in this disclosure is complete and accurate.
Elizabeth Shpall
Sep 19, 2019 15:18:48 EDT
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

Company or Organizat ion

Ent it y T ype Int erest Held By

Celgene Other Self

Category: Other Consultant Description:

Contract Description: Advisory Board Additional Information:

Novart is Other Self

Category: Other Consultant Description:

Contract Description: advisory board Additional Information:

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

3. Are you t he corresponding aut hor?

No.

C ertification

I certify that the information provided in this disclosure is complete and accurate.
Peter Thall
Sep 25, 2019 16:34:10 EDT
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

IL-15 armored CAR-transduced NK cells against CD19 positive B cell tumors

3. Are you t he corresponding aut hor?

No.

C ertification

I certify that the information provided in this disclosure is complete and accurate.
Philip Thompson
Nov 06, 2019 17:39:10 EST
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

IL-15 Armored CAR-Transduced NK Cells Against CD19 Positive B Cell Tumors

3. Are you t he corresponding aut hor?

No.

C ertification

I certify that the information provided in this disclosure is complete and accurate.
Michael Wang
Oct 08, 2019 11:58:35 EDT
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

Company or Organizat ion

Ent it y T ype Int erest Held By

Acert a Pharma, LLC Grant / Contract Self

Recipient Name: Recipient Type:

Grant / Contract Description: Grant / Contract Purpose:
Additional Information:

Ast raZ eneca Grant / Contract Self

Recipient Name: Recipient Type:

Grant / Contract Description: Grant / Contract Purpose:
Additional Information:

Ast raZ eneca Consultant Self

Category: Consultant Consultant Description:

Contract Description: Additional Information:

Aviara Grant / Contract Self

Recipient Name: Recipient Type:

Grant / Contract Description: Grant / Contract Purpose:
Additional Information:

BeiGene Grant / Contract Self

Recipient Name: Recipient Type:

Grant / Contract Description: Grant / Contract Purpose:
Additional Information:

BioInvent Grant / Contract Self

Recipient Name: Michael Wang Recipient Type: Institution

Grant / Contract Description: Pre-clinical research funding Grant / Contract Purpose: Research
Additional Information:

Celgene Grant / Contract Self

Recipient Name: Recipient Type:

Grant / Contract Description: Grant / Contract Purpose:
Additional Information:

Celgene Consultant Self

Category: Consultant Consultant Description:

Contract Description: Additional Information:

Janssen Global Services, LLC Grant / Contract Self

Recipient Name: Recipient Type:

Grant / Contract Description: Grant / Contract Purpose:
Additional Information:
 Juno T herapeut ics Grant / Contract Self

Recipient Name: Recipient Type:

Grant / Contract Description: Grant / Contract Purpose:
Additional Information:

Kit e Pharma Grant / Contract Self

Recipient Name: Recipient Type:

Grant / Contract Description: Grant / Contract Purpose:
Additional Information:

Kit e Pharma Consultant Self

Category: Consultant Consultant Description:

Contract Description: Additional Information:

Loxo Oncology Grant / Contract Self

Recipient Name: Recipient Type:

Grant / Contract Description: Grant / Contract Purpose:
Additional Information:

Loxo Oncology Consultant Self

Category: Consultant Consultant Description:

Contract Description: Additional Information:

MoreHealt h Consultant Self

Category: Consultant Consultant Description:

Contract Description: Additional Information:

MoreHealt h Stock Self

Additional Information:

Pharmacyclics LLC, An AbbVie Company Grant / Contract Self

Recipient Name: Michael Wang Recipient Type: Institution

Grant / Contract Description: Clinical research funding Grant / Contract Purpose: Research
Additional Information:

Pharmacyclics LLC, An AbbVie Company Consultant Self

Category: Consultant Consultant Description:

Contract Description: Additional Information:

Pulse Biosciences Consultant Self

Category: Consultant Consultant Description:

Contract Description: Additional Information:

T arget ed Oncology Consultant Self

Category: Consultant Consultant Description:

Contract Description: Additional Information:

Velosbio, Inc Grant / Contract Self

Recipient Name: Recipient Type:

Grant / Contract Description: Grant / Contract Purpose:
Additional Information:

Additional Information:
 1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

3. Are you t he corresponding aut hor?

Yes.

a. Please list t he ot her aut hors' names here.

C ertification

I certify that the information provided in this disclosure is complete and accurate.
William Wierda
Nov 07, 2019 12:53:17 EST
New Engl and J our nal of M edi ci ne

Disclosure Purpose: 19-10 60 7

Summary of Financial Interests

Company or Organizat ion

Ent it y T ype Int erest Held By

AbbVie Travel Self

Location(s): Various destinations Purpose: Present/Speak about CLL

Additional Information:

Acert a Pharma Travel Self

Location(s): Various destinations Purpose: Present/Speak about CLL/Leukemia

Additional Information:

Cyclacel Other Self

Category: Other Consultant Description:

Contract Description: Research funding to MD Anderson Cancer Center's Additional Information:
research efforts.

Genent ech Travel Self

Location(s): Various destinations Purpose: Present/Speak about CLL/Leukemia

Additional Information:

Gilead Sciences Travel Self

Location(s): Various destinations Purpose: Present/Speak about CLL/Leukemia

Additional Information:

Janssen Biot ech, Inc. Travel Self

Location(s): Various destinations Purpose: Present/Speak about CLL/Leukemia

Additional Information:

Juno T herapeut ics Travel Self

Location(s): Various destinations Purpose: Present/Speak about CLL/Leukemia

Additional Information:

KIT E Pharma Travel Self

Location(s): Various destinations Purpose: Present/Speak about CLL/Leukemia

Additional Information:

Loxo Other Self

Category: Other Consultant Description:

Contract Description: Research funding to MD Anderson Cancer Center's Additional Information:
research efforts.

Miragen Other Self

Category: Other Consultant Description:

Contract Description: Research funding to MD Anderson Cancer Center's Additional Information:
research efforts.
 Novart is Other Self

Category: Other Consultant Description:

Contract Description: Research funding to MD Anderson Cancer Center's Additional Information:
research efforts.

Onct ernal T herapeuct ics Inc Travel Self

Location(s): Various destinations Purpose: Present/Speak about CLL/Leukemia

Additional Information:

Pharmacyclics LLC, An AbbVie Company Travel Self

Location(s): Various destinations Purpose: Present/Speak about CLL/Leukemia

Additional Information:

Sunesis Other Self

Category: Other Consultant Description:

Contract Description: Research funding to MD Anderson Cancer Center's Additional Information:
research efforts.

Xencor Other Self

Category: Other Consultant Description:

Contract Description: Research funding to MD Anderson Cancer Center's Additional Information:
research efforts.

Additional Information:

1. Are t here ot her relat ionships or act ivit ies t hat readers could perceive t o have inf luenced, or t hat give t he appearance
of pot ent ially inf luencing, what you wrot e in t he submit t ed work?

No.

2. What is t he manuscript t it le?

3. Are you t he corresponding aut hor?

C ertification

I certify that the information provided in this disclosure is complete and accurate.